Solanezumab is a drug that can stop the development of Alzheimer’s disease because it prevents the formation of protein plaques that form in the brain, cause the onset of the disease and cause symptoms such as memory loss, disorientation and difficulty speaking. For more information about the disease, see: Symptoms of Alzheimer’s Disease.
Although this drug is not yet on sale, it is being developed by pharmaceutical company Eli Lilly.
- Solanezumab is a dementia-fighting drug used to stop the development of Alzheimer’s disease early.
- When the patient has few symptoms.
Thus, Solanezumab helps the patient to conserve memory and does not develop symptoms as quickly as disorientation, inability to identify object function or difficulty speaking, for example.
This drug prevents the development of protein plaques that form in the brain and are responsible for the development of Alzheimer’s disease, acting on beta-amyloid plaques, which accumulate in hippocampus neurons and the basal nucleus of meyenert.
Solanezumab is a medicine that should be indicated by the psychiatrist, and tests indicate that at least 400 mg per injection into the vein should be given for about 7 months.